201286-96-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Methyl-1H-indazole-6-carboxylic acid is used as a key intermediate in the synthesis of novel drug candidates for various therapeutic applications. Its unique chemical structure allows for the development of new compounds with potential pharmacological effects.
Used in Medicinal Chemistry Research:
3-Methyl-1H-indazole-6-carboxylic acid serves as an important compound in medicinal chemistry research, where it is studied for its potential biological activity and pharmacological effects. This research aims to uncover its therapeutic potential and contribute to the discovery of new drugs for treating various diseases.

Upstream product

• 540-80-7 tert.-butylnitrite 
• 5129-23-7 3-Amino-4-ethyl benzoic acid 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 
• 201286-99-9 3-methyl-1H-indazol-6-ol 
• 7746-29-4 6-methoxy-3-methyl-1H-indazole 
• 619-64-7 p-ethylbenzoic acid 
• 103440-95-5 4-Ethyl-3-nitrobenzoic acid 
• 201286-98-8 3-methyl-1-[(trifluoromethyl)sulfonyl]-1H-indazol-6-yl trifluoromethanesulfonate 
• 201286-97-7 methyl 3-methyl-1-[(trifluoromethyl)sulfonyl]-1H-indazole-6-carboxylate 

Downstream Products

• 201286-95-5 6-(methoxycarbonyl)-3-methyl-1H-indazole 
• 219764-09-7 1-(4-bromo-2-chlorobenzyl)-6-carboxy-3-methyl-1H-indazole 
• 219763-47-0 6-carboxy-1-(2,4-dichlorobenzyl)-3-methyl-1H-indazole 
• 219764-07-5 6-carboxy-1-(2-chloro-4-phenylbenzyl)-3-methyl-1H-indazole 

Relevant academic research and scientific papers

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.